Financial Daily from THE HINDU group of publications
Monday, Jul 04, 2005
Financial Daily from THE HINDU group of publications Monday, Jul 04, 2005 |
|
|
|
|
|
Corporate
-
Announcements Aurobindo Pharma gets US approval for Efavirenz Our Bureau
Hyderabad , July 3 AUROBINDO Pharma Ltd on Sunday announced that it has received approval from the US Food and Drug Administration for Efavirenz tablets, 600 mg, which it claims is the first generic approval given to it ahead of the rest of the industry. Efavirenz is a key anti-retro viral (ARV) for AIDS therapy. This is the third ARV approval with the other products being Neviraphine and Lumivudine. Efavirenz represents a significant opportunity in Africa for Aurobindo under the PEPFAR (the President's Emergency Plan for AIDS relief) programme. PEPFAR is a five-year programme backed by the US Government to fight the HIV/AIDS pandemic. According to a statement from Aurobindo, Efavirenz is internationally referred to as Susitva, which is manufactured by Bristol Myers Squibb Co.
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2005, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|